

ADVANCED MEDICAL OPTICS INC  
Form 424B3  
January 09, 2006

**Prospectus Supplement  
(to Prospectus dated October 5, 2004)**

**Filed Pursuant to Rule 424(b)(3)  
Registration No. 333-118922**

**ADVANCED MEDICAL OPTICS, INC.**

**\$350,000,000**

**2.50% Convertible Senior Subordinated Notes due 2024**

**and**

**Shares of Common Stock Issuable Upon Conversion of the Notes**

This prospectus supplement supplements the prospectus dated October 5, 2004, as supplemented by prospectus supplements dated October 19, 2004, November 4, 2004, November 10, 2004, December 13, 2004, January 11, 2005, February 7, 2005, March 18, 2005, April 20, 2005, May 24, 2005, July 28, 2005, October 14, 2005, November 16, 2005 and December 7, 2005 relating to the resale by certain of our securityholders of up to \$350,000,000 aggregate principal amount at maturity of our 2.50% Convertible Senior Subordinated Notes due 2024 and the shares of our common stock issuable upon conversion of the notes. You should read this prospectus supplement in conjunction with the prospectus. This prospectus supplement is qualified by reference to the prospectus, except to the extent that the information in this prospectus supplement supersedes the information contained in the prospectus.

Effective December 15, 2004, as permitted by the indenture governing the notes, we made an irrevocable election to satisfy in cash our conversion obligation with respect to the principal amount of any notes converted after December 15, 2004, with any remaining amount of the conversion obligation to be satisfied in shares of common stock, in each case, calculated as set forth in the indenture.

The information appearing under the heading "Selling Securityholders" in the prospectus is hereby amended by the addition or substitution, as applicable, of the following:

<b>Name of Selling Securityholder</b>	<b>Aggregate Principal Amount of Notes That May Be Sold</b>	<b>Percentage of Aggregate Principal Amount of Notes</b>	<b>Number of Shares of Common Stock</b>	<b>Percentage of Common Stock Outstanding (1)</b>
---------------------------------------	---	--	---	---

## Edgar Filing: ADVANCED MEDICAL OPTICS INC - Form 424B3

		<b>Outstanding</b>	<b>That May Be Sold(1)</b>	
Guardian Life Insurance Co. (2)(3)(4)	\$6,400,000	1.8%	(1)	(1)

---

- (1) As a result of our irrevocable election to satisfy in cash our conversion obligation with respect to the principal amount of any notes converted after December 15, 2004, on conversion, each holder will receive (A) a cash amount equal to the aggregate principal amount of the notes to be converted, and (B) a number of shares of common stock equal to (i) the aggregate principal amount of notes to be converted divided by 1,000 and multiplied by (ii)(a) the conversion rate then in effect minus (b) \$1,000 divided by the applicable stock price (as defined in the prospectus and the indenture). The initial conversion rate of the notes is 19.9045 shares of common stock per \$1,000 principal amount at maturity of the notes, subject to adjustment as described in the prospectus and the indenture.
  - (2) John Murphy, Managing Director of Guardian Life Insurance Co., has dispositive power over the notes and voting and dispositive power over the common stock underlying the notes held by this selling securityholder.
  - (3) Includes \$4,400,000 aggregate principal amount of notes previously reflected in the prospectus dated October 5, 2004, plus an additional \$2,000,000 aggregate principal amount of notes subsequently acquired by the selling securityholder.
  - (4) The selling securityholder has identified itself as an affiliate of a broker-dealer. Such selling securityholder has informed us that: (1) such selling securityholder purchased its notes in the ordinary course of business, and (2) at the time that the notes were purchased, the selling securityholder had no agreements or understandings, directly or indirectly, with any person to distribute the notes.
- 

**Investing in the notes and our common stock issuable upon conversion of the notes involves risks that are described in the Risk Factors section of the accompanying prospectus beginning on page 13.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this prospectus supplement is January 6, 2006

